INCA036873 / Incyte, Merus - LARVOL DELTA

INCA036873, a first-in-class CD70×CD3 T cell-redirecting bispecific antibody, for the treatment of CD70-positive malignancies (AACR 2026) - "Importantly, INCA036873 exhibited a favorable safety profile, with limited cytokine release in human whole blood cytokine release assays and no adverse findings at doses up to 3.0 mg/kg (>15-fold above the projected therapeutic exposure) in a 4-week toxicology study in huCD70/huCD3EDG knock-in mice. INCA036873 also demonstrated desirable pharmacokinetics in cynomolgus monkeys.Overall, these data support the advancement of INCA036873 as a promising, potential, first-in-class bispecific T-cell engager antibody for CD70-positive malignancies."

Bispecific • IO biomarker • Acute Myelogenous Leukemia • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • CD27 • CD34 • CD70 • TNFA

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies (clinicaltrials.gov) - P1 | N=280 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies (clinicaltrials.gov) - P1 | N=280 | Not yet recruiting | Sponsor: Incyte Corporation

New P1 trial • Hematological Malignancies • Oncology • Solid Tumor